StockNews.com Begins Coverage on Global Cord Blood (NYSE:CO)

Research analysts at StockNews.com started coverage on shares of Global Cord Blood (NYSE:CO) in a research report issued to clients and investors on Friday. The firm set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Price Performance

NYSE CO opened at $1.30 on Friday. The firm has a market cap of $158.02 million, a price-to-earnings ratio of 2.03 and a beta of 0.16. The business has a 50-day moving average price of $1.54 and a 200-day moving average price of $1.36. Global Cord Blood has a twelve month low of $2.03 and a twelve month high of $5.50.

Hedge Funds Weigh In On Global Cord Blood

A number of hedge funds have recently made changes to their positions in CO. Northern Trust Corp bought a new position in shares of Global Cord Blood in the second quarter worth about $96,000. Natixis Advisors L.P. boosted its stake in shares of Global Cord Blood by 5.6% in the second quarter. Natixis Advisors L.P. now owns 199,880 shares of the medical research company’s stock worth $592,000 after acquiring an additional 10,550 shares during the period. Finally, Moneta Group Investment Advisors LLC lifted its position in shares of Global Cord Blood by 99,844.5% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 26,093,520 shares of the medical research company’s stock worth $77,957,000 after buying an additional 26,067,412 shares in the last quarter.

Global Cord Blood Company Profile

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.